BACKGROUND & AIMS Quantification of anti-HBs and anti-HBc predicts the risk of HBV reactivation (HBVr) in lymphoma patients receiving rituximab treatment. However, it remains unclear whether the quantification is predictive of HBVr in leukemia patients undergoing immunosuppression. METHODS and patients: Clinical and laboratory data of the leukemia patients with resolved HBV infection diagnosed between January 2013 and March 2018 were retrospectively collected. Data series of HBV seromarkers and HBV DNA levels before the patients receiving chemotherapy and/or hematopoietic stem cell transplantation (HSCT) and during follow-up duration were analyzed. RESULTS In total, 533 leukemia patients with resolved HBV infection were included. The incidences of HBVr were 5.7% (25/441) and 2.2% (2/92) in patients receiving HSCT and chemotherapy, respectively. In patients receiving HSCT, acute lymphoid leukemia had a significantly higher incidence of HBVr than acute myeloid leukemia (8.9% vs 3.9%, P < 0.05). The incidence varied almost zero to 40% due to the differences in the profiles of HBV antibodies. High anti-HBs (cut-off of 79.2 IU/L) or low anti-HBc levels (cut-off of 4.475, S/CO) at baseline were associated with a low risk of HBVr. Anti-HBe status did not affect the incidence of HBVr. However, the cut-offs were only predictive of HBVr in the patients who had negative anti-HBe. CONCLUSION The baseline profiles of HBV antibodies are predictive of the risk of HBVr in leukemia patients undergoing immunosuppression. However, seronegative anti-HBe is a prerequisite for using baseline anti-HBs and anti-HBc quantification to predict HBVr risk.

中文翻译：

---

乙型肝炎抗体在预测白血病患者中已解决的乙型肝炎病毒感染的重新激活中的作用。

背景与目的对抗HBs和抗HBc的量化预测了接受利妥昔单抗治疗的淋巴瘤患者发生HBV活化（HBVr）的风险。但是，尚不清楚该定量是否可预测正在接受免疫抑制的白血病患者中的HBVr。方法和患者：回顾性收集2013年1月至2018年3月期间诊断为HBV感染的白血病患者的临床和实验室数据。在接受化疗和/或造血干细胞移植（HSCT）的患者以及随访期间，分析了HBV血清标志物和HBV DNA水平的数据系列。结果总共纳入了533例解决了HBV感染的白血病患者。在接受HSCT和化疗的患者中HBVr的发生率分别为5.7％（25/441）和2.2％（2/92），分别。在接受HSCT的患者中，急性淋巴细胞白血病的HBVr发生率明显高于急性髓细胞性白血病（8.9％vs 3.9％，P <0.05）。由于HBV抗体谱的差异，发病率几乎为零至40％。基线时高抗HBs（临界值79.2 IU / L）或低抗HBc水平（临界值4.475，S / CO）与低HBVr风险相关。抗HBe状态不影响HBVr的发生率。但是，这些临界值仅是抗HBe阴性患者中HBVr的预测指标。结论HBV抗体的基线概况可预测接受免疫抑制的白血病患者中HBVr的风险。但是，血清阴性抗HBe是使用基线抗HBs和抗HBc定量预测HBVr风险的先决条件。急性淋巴性白血病的HBVr发生率明显高于急性髓性白血病（8.9％比3.9％，P <0.05）。由于HBV抗体谱的差异，发病率几乎为零至40％。基线时高抗HBs（临界值79.2 IU / L）或低抗HBc水平（临界值4.475，S / CO）与低HBVr风险相关。抗HBe状态不影响HBVr的发生率。但是，这些临界值仅是抗HBe阴性患者中HBVr的预测指标。结论HBV抗体的基线概况可预测接受免疫抑制的白血病患者中HBVr的风险。但是，血清阴性抗HBe是使用基线抗HBs和抗HBc定量预测HBVr风险的先决条件。急性淋巴性白血病的HBVr发生率明显高于急性髓性白血病（8.9％比3.9％，P <0.05）。由于HBV抗体谱的差异，发病率几乎为零至40％。基线时高抗-HBs（临界值79.2 IU / L）或低抗-HBc水平（临界值4.475，S / CO）与HBVr低风险相关。抗HBe状态不影响HBVr的发生率。但是，这些临界值仅是抗HBe阴性患者中HBVr的预测指标。结论HBV抗体的基线概况可预测接受免疫抑制的白血病患者中HBVr的风险。但是，血清阴性抗HBe是使用基线抗HBs和抗HBc定量预测HBVr风险的先决条件。